20 results on '"Choi, Hannah"'
Search Results
2. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis.
- Author
-
Anderson, Ryan T., Choi, Hannah S.J., Lenz, Oliver, Peters, Marion G., Janssen, Harry L.A., Mishra, Poonam, Donaldson, Eric, Westman, Gabriel, Buchholz, Stephanie, Miller, Veronica, and Hansen, Bettina E.
- Abstract
Seroclearance of hepatitis B surface antigen (HBsAg) is the desired end point of treatment for chronic hepatitis B virus (HBV) infection, according to guidelines. We performed a systematic review and meta-analysis to evaluate the strength of the association between HBsAg seroclearance and long-term clinical outcomes. We performed a systematic review of the PubMed, EMBASE, and Cochrane Library databases for articles that assessed HBsAg status and reported the incidence of hepatocellular carcinoma (HCC), liver decompensation, liver transplantation, and/or all-cause mortality during follow-up evaluation. We performed a meta-analysis of rate ratios (RR) using a random-effects model independently for each end point and for a composite end point. We analyzed data from 28 studies, comprising a total of 188,316 patients with chronic HBV infection (treated and untreated), and 1,486,081 person-years (PY) of follow-up evaluation; 26 reported data on HCC, 7 on liver decompensation, and 13 on liver transplantation and/or death. The composite event rates were 0.19/1000 PY for the HBsAg seroclearance group and 2.45/1000 PY for the HBsAg-persistent group. Pooled RRs for the HBsAg seroclearance group were 0.28 for liver decompensation (95% CI, 0.13–0.59; P =.001), 0.30 for HCC (95% CI, 0.20–0.44; P <.001), 0.22 for liver transplantation and/or death (95% CI, 0.13–0.39; P <.001), and 0.31 for the composite end point (95% CI, 0.23–0.43; P <.001). No differences in RR estimates were observed among subgroups of different study or patient characteristics. In a systematic review and meta-analysis, we found seroclearance of HBsAg to be associated significantly with improved patient outcomes. The results are consistent among different types of studies, in all patient subpopulations examined, and support the use of HBsAg seroclearance as a primary end point of trials of patients with chronic HBV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. HDAC inhibitors improve CRISPR-mediated HDR editing efficiency in iPSCs
- Author
-
Zhang, Jian-Ping, Yang, Zhi-Xue, Zhang, Feng, Fu, Ya-Wen, Dai, Xin-Yue, Wen, Wei, Zhang, Beldon, Choi, Hannah, Chen, Wanqiu, Brown, Meredith, Baylink, David, Zhang, Lei, Qiu, Hongyu, Wang, Charles, Cheng, Tao, and Zhang, Xiao-Bing
- Abstract
Genome-edited human induced pluripotent stem cells (iPSCs) hold great promise for therapeutic applications. However, low editing efficiency has hampered the applications of CRISPR-Cas9 technology in creating knockout and homology-directed repair (HDR)-edited iPSC lines, particularly for silent genes. This is partially due to chromatin compaction, inevitably limiting Cas9 access to the target DNA. Among the six HDAC inhibitors we examined, vorinostat, or suberoylanilide hydroxamic acid (SAHA), led to the highest HDR efficiency at both open and closed loci, with acceptable toxicity. HDAC inhibitors equally increased non-homologous end joining (NHEJ) editing efficiencies (∼50%) at both open and closed loci, due to the considerable HDAC inhibitor-mediated increase in Cas9 and sgRNA expression. However, we observed more substantial HDR efficiency improvement at closed loci relative to open chromatin (2.8 vs. 1.7-fold change). These studies provide a new strategy for HDR-editing of silent genes in iPSCs.
- Published
- 2021
- Full Text
- View/download PDF
4. Active sensing with predictive coding and uncertainty minimization
- Author
-
Sharafeldin, Abdelrahman, Imam, Nabil, and Choi, Hannah
- Abstract
We present an end-to-end architecture for embodied exploration inspired by two biological computations: predictive coding and uncertainty minimization. The architecture can be applied to any exploration setting in a task-independent and intrinsically driven manner. We first demonstrate our approach in a maze navigation task and show that it can discover the underlying transition distributions and spatial features of the environment. Second, we apply our model to a more complex active vision task, whereby an agent actively samples its visual environment to gather information. We show that our model builds unsupervised representations through exploration that allow it to efficiently categorize visual scenes. We further show that using these representations for downstream classification leads to superior data efficiency and learning speed compared to other baselines while maintaining lower parameter complexity. Finally, the modular structure of our model facilitates interpretability, allowing us to probe its internal mechanisms and representations during exploration.
- Published
- 2024
- Full Text
- View/download PDF
5. Survey of spiking in the mouse visual system reveals functional hierarchy
- Author
-
Siegle, Joshua H., Jia, Xiaoxuan, Durand, Séverine, Gale, Sam, Bennett, Corbett, Graddis, Nile, Heller, Greggory, Ramirez, Tamina K., Choi, Hannah, Luviano, Jennifer A., Groblewski, Peter A., Ahmed, Ruweida, Arkhipov, Anton, Bernard, Amy, Billeh, Yazan N., Brown, Dillan, Buice, Michael A., Cain, Nicolas, Caldejon, Shiella, Casal, Linzy, Cho, Andrew, Chvilicek, Maggie, Cox, Timothy C., Dai, Kael, Denman, Daniel J., de Vries, Saskia E. J., Dietzman, Roald, Esposito, Luke, Farrell, Colin, Feng, David, Galbraith, John, Garrett, Marina, Gelfand, Emily C., Hancock, Nicole, Harris, Julie A., Howard, Robert, Hu, Brian, Hytnen, Ross, Iyer, Ramakrishnan, Jessett, Erika, Johnson, Katelyn, Kato, India, Kiggins, Justin, Lambert, Sophie, Lecoq, Jerome, Ledochowitsch, Peter, Lee, Jung Hoon, Leon, Arielle, Li, Yang, Liang, Elizabeth, Long, Fuhui, Mace, Kyla, Melchior, Jose, Millman, Daniel, Mollenkopf, Tyler, Nayan, Chelsea, Ng, Lydia, Ngo, Kiet, Nguyen, Thuyahn, Nicovich, Philip R., North, Kat, Ocker, Gabriel Koch, Ollerenshaw, Doug, Oliver, Michael, Pachitariu, Marius, Perkins, Jed, Reding, Melissa, Reid, David, Robertson, Miranda, Ronellenfitch, Kara, Seid, Sam, Slaughterbeck, Cliff, Stoecklin, Michelle, Sullivan, David, Sutton, Ben, Swapp, Jackie, Thompson, Carol, Turner, Kristen, Wakeman, Wayne, Whitesell, Jennifer D., Williams, Derric, Williford, Ali, Young, Rob, Zeng, Hongkui, Naylor, Sarah, Phillips, John W., Reid, R. Clay, Mihalas, Stefan, Olsen, Shawn R., and Koch, Christof
- Abstract
The anatomy of the mammalian visual system, from the retina to the neocortex, is organized hierarchically1. However, direct observation of cellular-level functional interactions across this hierarchy is lacking due to the challenge of simultaneously recording activity across numerous regions. Here we describe a large, open dataset—part of the Allen Brain Observatory2—that surveys spiking from tens of thousands of units in six cortical and two thalamic regions in the brains of mice responding to a battery of visual stimuli. Using cross-correlation analysis, we reveal that the organization of inter-area functional connectivity during visual stimulation mirrors the anatomical hierarchy from the Allen Mouse Brain Connectivity Atlas3. We find that four classical hierarchical measures—response latency, receptive-field size, phase-locking to drifting gratings and response decay timescale—are all correlated with the hierarchy. Moreover, recordings obtained during a visual task reveal that the correlation between neural activity and behavioural choice also increases along the hierarchy. Our study provides a foundation for understanding coding and signal propagation across hierarchically organized cortical and thalamic visual areas.
- Published
- 2021
- Full Text
- View/download PDF
6. Association Between the Presence of Metabolic Comorbidities and Liver-Related Events in Patients With Chronic Hepatitis B.
- Author
-
Patmore, Lesley A., Katwaroe, Warshan K., van der Spek, Daniel, Choi, Hannah S.J., Patel, Keyur, Brakenhoff, Sylvia, van der Meer, Adriaan J., Brouwer, Willem P., van Kleef, Laurens A., de Knegt, Rob J., Hansen, Bettina E., de Man, Rob A., Feld, Jordan J., Janssen, Harry L.A., and Sonneveld, Milan J.
- Abstract
Patients with chronic hepatitis B (CHB) are at increased risk of hepatocellular carcinoma and (liver-related) mortality. In addition to hepatitis B–related factors, metabolic comorbidities may contribute to the progression of fibrosis. Therefore, we studied the association between metabolic comorbidities and adverse clinical outcomes in patients with CHB. We conducted a retrospective cohort study of CHB patients attending the Erasmus MC University Medical Center (Rotterdam, The Netherlands) and CHB patients who underwent liver biopsy at the Toronto General Hospital (Toronto, Canada). The presence of metabolic comorbidities (ie, overweight, diabetes mellitus, hypertension, and dyslipidemia) was assessed based on chart review. The primary end point was liver-related events, defined as the first composite of hepatocellular carcinoma, liver transplantation, or liver-related mortality. We analyzed 1850 patients, of whom 926 (50.1%) were overweight, 161 (8.7%) had hypertension, 116 (6.3%) had dyslipidemia, and 82 (4.4%) had diabetes. During a median follow-up period of 7.3 years (interquartile range, 2.9–11.5 y), a total of 111 first events were recorded. Hypertension (hazard ratio [HR], 8.3; 95% CI, 5.5–12.7), diabetes (HR, 5.4; 95% CI, 3.2–9.1), dyslipidemia (HR, 2.8; 95% CI, 1.6–4.8), and overweight (HR, 1.7; 95% CI, 1.1–2.5) were associated with an increased risk for liver-related events. The presence of multiple comorbidities further increased the risk. Findings were consistent for patients with and without cirrhosis, among noncirrhotic hepatitis B e antigen–negative patients with hepatitis B virus DNA less than 2000 IU/mL and in multivariable analysis adjusting for age, sex, ethnicity, hepatitis B e antigen status, hepatitis B virus DNA, use of antiviral therapy, and the presence of cirrhosis. Metabolic comorbidities in CHB patients are associated with an increased risk for liver-related events, with the highest risk observed in patients with multiple comorbidities. Findings were consistent in various clinically relevant subgroups, underscoring the need for thorough metabolic assessment in patients with CHB. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Hierarchical organization of cortical and thalamic connectivity
- Author
-
Harris, Julie A., Mihalas, Stefan, Hirokawa, Karla E., Whitesell, Jennifer D., Choi, Hannah, Bernard, Amy, Bohn, Phillip, Caldejon, Shiella, Casal, Linzy, Cho, Andrew, Feiner, Aaron, Feng, David, Gaudreault, Nathalie, Gerfen, Charles R., Graddis, Nile, Groblewski, Peter A., Henry, Alex M., Ho, Anh, Howard, Robert, Knox, Joseph E., Kuan, Leonard, Kuang, Xiuli, Lecoq, Jerome, Lesnar, Phil, Li, Yaoyao, Luviano, Jennifer, McConoughey, Stephen, Mortrud, Marty T., Naeemi, Maitham, Ng, Lydia, Oh, Seung Wook, Ouellette, Benjamin, Shen, Elise, Sorensen, Staci A., Wakeman, Wayne, Wang, Quanxin, Wang, Yun, Williford, Ali, Phillips, John W., Jones, Allan R., Koch, Christof, and Zeng, Hongkui
- Abstract
The mammalian cortex is a laminar structure containing many areas and cell types that are densely interconnected in complex ways, and for which generalizable principles of organization remain mostly unknown. Here we describe a major expansion of the Allen Mouse Brain Connectivity Atlas resource1, involving around a thousand new tracer experiments in the cortex and its main satellite structure, the thalamus. We used Cre driver lines (mice expressing Cre recombinase) to comprehensively and selectively label brain-wide connections by layer and class of projection neuron. Through observations of axon termination patterns, we have derived a set of generalized anatomical rules to describe corticocortical, thalamocortical and corticothalamic projections. We have built a model to assign connection patterns between areas as either feedforward or feedback, and generated testable predictions of hierarchical positions for individual cortical and thalamic areas and for cortical network modules. Our results show that cell-class-specific connections are organized in a shallow hierarchy within the mouse corticothalamic network.
- Published
- 2019
- Full Text
- View/download PDF
8. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study
- Author
-
Sonneveld, Milan J, Brouwer, Willem P, Chan, Henry L-Y, Piratvisuth, Teerha, Jia, Ji-Dong, Zeuzem, Stefan, Liaw, Yun-Fan, Hansen, Bettina E, Choi, Hannah, Wat, Cynthia, Pavlovic, Vedran, Gaggar, Anuj, Xie, Qing, Buti, Maria, de Knegt, Robert J, and Janssen, Harry L A
- Abstract
Ruling out the presence of cirrhosis is important for the management of chronic hepatitis B. We aimed to study and optimise the performance of two non-invasive indices for ruling out cirrhosis: the aspartate aminotransferase-platelet ratio index (APRI) and fibrosis score based on four factors (FIB-4).
- Published
- 2019
- Full Text
- View/download PDF
9. Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B.
- Author
-
Choi, Hannah S.J., Hirode, Grishma, Chen, Chien-Hung, Su, Tung-Hung, Seto, Wai-Kay, Van Hees, Stijn, Papatheodoridi, Margarita, Lens, Sabela, Wong, Grace L.H., Brakenhoff, Sylvia M., Chien, Rong-Nan, Feld, Jordan J., Sonneveld, Milan J., Chan, Henry L.Y., Forns, Xavier, Papatheodoridis, George V., Vanwolleghem, Thomas, Yuen, Man-Fung, Hsu, Yao-Chun, and Kao, Jia-Horng
- Abstract
Whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) differentially affect relapse and outcomes following treatment discontinuation across different patient subpopulations remains unclear. We aimed to compare rates of off-therapy hepatitis B surface antigen (HBsAg) loss, virological and clinical relapse, and retreatment between chronic hepatitis B (CHB) patients who discontinued TDF or ETV therapy. This study included 1402 virally suppressed CHB patients who stopped either ETV (n = 981) or TDF (n = 421) therapy between 2001 and 2020 from 13 participating centers across North America, Europe, and Asia. All patients were hepatitis B e antigen–negative at treatment discontinuation. Inverse probability of treatment weighting was used to balance the treatment groups. Outcomes were analyzed using survival methods. During a median off-treatment follow-up of 18 months, HBsAg loss occurred in 96 (6.8%) patients overall. Compared with ETV, TDF was associated with a higher rate of HBsAg loss (P =.03); however, the association was no longer significant after statistical adjustment (P =.61). Virological relapse occurred earlier among TDF-treated patients (P <.01); nonetheless, rates became comparable after the first year off therapy (P =.49). TDF was significantly associated with a higher clinical relapse rate than ETV throughout follow-up (P <.01). The development of a virological or clinical relapse did not affect the rate of HBsAg loss. Retreatment rates were not significantly different between the treatment groups. TDF and ETV have differential relapse patterns but are associated with similar rates of HBsAg loss and retreatment following discontinuation. Finite therapy can be considered for CHB patients on either TDF or ETV therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Synthesis of one-dimensional SnO lines by using electrohydrodynamic jet printing for a NO gas sensor.
- Author
-
Kim, Chang-Yeoul, Jung, Hyunsung, Choi, Hannah, and Choi, Duck-kyun
- Published
- 2016
- Full Text
- View/download PDF
11. Synthesis of one-dimensional SnO2lines by using electrohydrodynamic jet printing for a NO gas sensor
- Author
-
Kim, Chang-Yeoul, Jung, Hyunsung, Choi, Hannah, and Choi, Duck-kyun
- Abstract
One-dimensional (1-D) SnO2lines as a representative semiconducting oxide were formed by using electrohydrodynamic (EHD) jet-printing of a tin chloride pentahydrate and polyvinylpyrrolidone (PVP, 1,200k, Aldrich) solution ink. The 1-D polymer lines, including Sn precursors, were created by controlling the viscosity, that is, the polymer/tin precursor ratio, and by adjusting printing conditions such as the tip-to-substrate distance, the applied voltage, the flow rate of ink and its velocity. The printed lines were dried at 200 °C to get rid of solvent and were finally heat-treated at 600 °C to burn out PVP and form a tin oxide line. We found that the linearity and the shape of the aligned 1-D SnO2could be controlled by adjusting various parameters such as the viscosity of the precursor solution, the ratio of Sn to the PVP polymer in the solution, the shape of the cone, the size of a droplet, the applied voltage, the working distance, and the flow rate on glass slides and Si wafers with a SiO2layer. We found that the heat treatment for removal of the polymers should be tailored to produce continuous 1-D SnO2lines due to the drastic volume reduction (> 90%) of the aligned fibers during the annealing process. The electrical and the NO-gas-sensing properties of the 1-D SnO2aligned on Si wafers with Au electrode patterns were evaluated.
- Published
- 2016
- Full Text
- View/download PDF
12. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
- Author
-
Hirode, Grishma, Choi, Hannah S.J., Chen, Chien-Hung, Su, Tung-Hung, Seto, Wai-Kay, Van Hees, Stijn, Papatheodoridi, Margarita, Lens, Sabela, Wong, Grace, Brakenhoff, Sylvia M., Chien, Rong-Nan, Feld, Jordan, Sonneveld, Milan J., Chan, Henry L.Y., Forns, Xavier, Papatheodoridis, George V., Vanwolleghem, Thomas, Yuen, Man-Fung, Hsu, Yao-Chun, and Kao, Jia-Horng
- Abstract
Functional cure, defined based on hepatitis B surface antigen (HBsAg) loss, is rare during nucleos(t)ide analogue (NA) therapy and guidelines on finite NA therapy have not been well established. We aim to analyze off-therapy outcomes after NA cessation in a large, international, multicenter, multiethnic cohort of patients with chronic hepatitis B (CHB). This cohort study included patients with virally suppressed CHB who were hepatitis B e antigen (HBeAg)–negative and stopped NA therapy. Primary outcome was HBsAg loss after NA cessation, and secondary outcomes included virologic, biochemical, and clinical relapse, alanine aminotransferase flare, retreatment, and liver-related events after NA cessation. Among 1552 patients with CHB, cumulative probability of HBsAg loss was 3.2% at 12 months and 13.0% at 48 months of follow-up. HBsAg loss was higher among Whites (vs Asians: subdistribution hazard ratio, 6.8; 95% confidence interval, 2.7–16.8; P <.001) and among patients with HBsAg levels <100 IU/mL at end of therapy (vs ≥100 IU/mL: subdistribution hazard ratio, 22.5; 95% confidence interval, 13.1–38.7; P <.001). At 48 months of follow-up, Whites with HBsAg levels <1000 IU/mL and Asians with HBsAg levels <100 IU/mL at end of therapy had a high predicted probability of HBsAg loss (>30%). Incidence rate of hepatic decompensation and hepatocellular carcinoma was 0.48 per 1000 person-years and 0.29 per 1000 person-years, respectively. Death occurred in 7/19 decompensated patients and 2/14 patients with hepatocellular carcinoma. The best candidates for NA withdrawal are virally suppressed, HBeAg- negative, noncirrhotic patients with CHB with low HBsAg levels, particularly Whites with <1000 IU/mL and Asians with <100 IU/mL. However, strict surveillance is recommended to prevent deterioration. [Display omitted] Nucleos(t)ide analogue withdrawal with close follow-up monitoring is beneficial to achieve functional cure among patients with virally suppressed chronic hepatitis B who are hepatitis B e antigen–negative with low hepatitis B surface antigen levels and without advanced liver disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection.
- Author
-
Choi, Hannah S.J., van Campenhout, Margo J.H., van Vuuren, Anneke J., Krassenburg, Lisette A.P., Sonneveld, Milan J., de Knegt, Robert J., Hansen, Bettina E., and Janssen, Harry L.A.
- Abstract
Interferon-alpha (IFN-α) treatment for chronic hepatitis B (CHB) virus infection is finite and leads to relatively higher functional cure rates (HBsAg loss) than nucleo(s)tide analogue (NA) therapy. Effects of pegylated (PEG)/conventional IFN-α treatment on clinical outcomes were evaluated in an ultra-long-term follow-up of CHB patients. HBeAg-positive patients treated with (PEG)IFN-α at a tertiary referral centre between 1977-2014 were included. We reviewed medical charts and consulted the municipal registry for patient information. Patients were invited for a single visit at the outpatient clinic in the case of missing follow-up data. The endpoints included serum HBeAg/HBsAg loss and incidence of clinical events, using life table methods and person-years to analyze the incidence of events. Patients were censored upon retreatment. The study cohort included 267 patients, 67% male, 58% Caucasian, with a median age of 32 years. The median follow-up duration was 11.5 years. The 5 and 10-year cumulative incidence of HBsAg loss were 14% and 32%, respectively. Baseline factors associated with a higher rate of HBsAg loss were male sex, Caucasian race, genotype A, age ≥40 years, and cirrhosis. HBsAg loss rates did not differ significantly between those who received short-term (≤24 weeks) vs long-term (>24 weeks) therapy. Both HBeAg and HBsAg loss were significantly associated with improved clinical outcomes. Early response (HBeAg loss) was associated with more HBsAg loss and better patient outcomes. During long-term follow-up, high rates of HBsAg loss were observed from a single (PEG)IFN-α course. Its persistent effects suggest that a role for IFN-α remains, potentially in novel combination therapies in search of a functional cure. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Impact of the 2018 Society of Critical Care Medicine Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Guidelines on Nonopioid Analgesic Use and Related Outcomes in Critically Ill Adults After Major Surgery
- Author
-
Sutton, Spencer, McCrobie, Trevor R., Kovacevic, Mary R., Dube, Kevin M., Szumita, Paul M., Herod, Kyle, Bezio, Aaron, Choi, Hannah, Duprey, Matthew S., Zeballos, Jose, and Devlin, John W.
- Abstract
We compared ICU nonopioid analgesic use, opioid use, and pain before and after Pain, Agitation/Sedation, Delirium, Immobility, and Sleep guideline publication at one academic center among critically ill adults receiving an opioid infusion and greater than or equal to 24 hours of mechanical ventilation after major surgery. The 2017 (n= 77) and 2019 (n= 57) groups were similar at baseline. The 2019 (vs 2017) patients were more likely to receive scheduled IV/oral acetaminophen (84% vs 69%; p= 0.05), less likely to receive a lidocaine patch (33% vs 50%; p= 0.05), and just as likely to receive ketamine (4% vs 3%; p= 1.0), an nonsteroidal anti-inflammatory drug (7% vs 3%; p= 0.26), or gabapentin/pregabalin (16% vs 9%; p= 0.23). Daily average opioid exposure (in IV morphine milligram equivalent) was not different (70 [42–99] [2017] vs 78 mg [49–109 mg]; p= 0.94). The 2019 (vs 2017) group spent more ICU days with severe pain (p= 0.04). At our center, Pain, Agitation/Sedation, Delirium, Immobility, and Sleep guideline publication had little effect on nonopioid analgesic or opioid prescribing practices in critically ill surgical adults.
- Published
- 2021
- Full Text
- View/download PDF
15. Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse
- Author
-
Zhang, Jian-Ping, Cheng, Xin-Xin, Zhao, Mei, Li, Guo-Hua, Xu, Jing, Zhang, Feng, Yin, Meng-Di, Meng, Fei-Ying, Dai, Xin-Yue, Fu, Ya-Wen, Yang, Zhi-Xue, Arakaki, Cameron, Su, Ruijun Jeanna, Wen, Wei, Wang, Wen-Tian, Chen, Wanqiu, Choi, Hannah, Wang, Charles, Gao, Guangping, Zhang, Lei, Cheng, Tao, and Zhang, Xiao-Bing
- Abstract
Background: Hemophilia A, a bleeding disorder resulting from F8mutations, can only be cured by gene therapy. A promising strategy is CRISPR-Cas9-mediated precise insertion of F8in hepatocytes at highly expressed gene loci, such as albumin (Alb). Unfortunately, the precise in vivo integration efficiency of a long insert is very low (~ 0.1%). Results: We report that the use of a double-cut donor leads to a 10- to 20-fold increase in liver editing efficiency, thereby completely reconstituting serum F8 activity in a mouse model of hemophilia A after hydrodynamic injection of Cas9-sgAlb and B domain-deleted (BDD) F8 donor plasmids. We find that the integration of a double-cut donor at the Alblocus in mouse liver is mainly through non-homologous end joining (NHEJ)-mediated knock-in. We then target BDDF8to multiple sites on introns 11 and 13 and find that NHEJ-mediated insertion of BDDF8restores hemostasis. Finally, using 3 AAV8 vectors to deliver genome editing components, including Cas9, sgRNA, and BDDF8donor, we observe the same therapeutic effects. A follow-up of 100 mice over 1 year shows no adverse effects. Conclusions: These findings lay the foundation for curing hemophilia A by NHEJ knock-in of BDDF8at Albintrons after AAV-mediated delivery of editing components.
- Published
- 2019
- Full Text
- View/download PDF
16. High-Dose TSLP Induces Co-Receptor Internalization and Signal Shutdown in Ph-like B-ALL with Overexpression of CRLF2
- Author
-
Watson, WayAnne B., Alkashgari, Hossam, Stoian, Cornelia, Coats, Jacqueline S., Baez, Ineavely, Choi, Hannah, Becerra, Benjamin, Chavan, Rishikesh, Kamal, Muhammad Omair, Gohar, Shadi Farzin, Meng, Xianmei, Dovat, Sinisa, Payne, Kimberly J., and Erjaee, Hoda
- Abstract
Coats: Elf Zone, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees. Meng:Elf Zone, Inc.: Employment. Dovat:Elf Zone, Inc.: Membership on an entity's Board of Directors or advisory committees. Payne:Elf Zone, Inc.: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees.
- Published
- 2018
- Full Text
- View/download PDF
17. High-Dose TSLP Induces Co-Receptor Internalization and Signal Shutdown in Ph-like B-ALL with Overexpression of CRLF2
- Author
-
Watson, WayAnne B., Alkashgari, Hossam, Stoian, Cornelia, Coats, Jacqueline S., Baez, Ineavely, Choi, Hannah, Becerra, Benjamin, Chavan, Rishikesh, Kamal, Muhammad Omair, Gohar, Shadi Farzin, Meng, Xianmei, Dovat, Sinisa, Payne, Kimberly J., and Erjaee, Hoda
- Abstract
Background. Approximately half of all Ph-like B cell acute lymphoblastic leukemia is characterized by overexpression of CRLF2 (CRLF2 B-ALL). CRLF2 B-ALL is associated with high rates of relapse and is more prevalent in Hispanic children with Native American ancestry. CRLF2, together with the IL-7 receptor alpha (IL-7Ra), comprises a receptor complex that is activated by the cytokine, TSLP. Receptor activation by TSLP induces JAK2/STAT5 and PI3/AKT/mTOR signals that promote survival and proliferation of leukemia cells. To study the role of TSLP in CRLF2 B-ALL, we developed a patient-derived xenograft (PDX) model of CRLF2 B-ALL that allows us to vary circulating levels of human TSLP (hTSLP) in a physiologic environment. We generated PDX from patients' CRLF2 B-ALL cells and compared leukemia burden in mice with varying levels of hTSLP. CRLF2 B-ALL cells grew robustly in PDX models with hTSLP levels at or below levels present in pediatric cancer patients (~10 pg/mL). In contrast, CRLF2 B-ALL cells were essentially eliminated in PDXs with hTSLP at high physiological levels (40-140 pg/mL). These data suggest that high physiologic levels of TSLP exert a potent anti-leukemia effect in Ph-like B-ALL with overexpression of CRLF2.
- Published
- 2018
- Full Text
- View/download PDF
18. Is intermittent amnioinfusion for variable decelerations better than continuous amnioinfusion with regard to fetal outcome?
- Author
-
Patel, Hema, Thompson, Kida, Choi, Hannah, and Kaur, Amandeep
- Published
- 2015
- Full Text
- View/download PDF
19. Biologic for the Treatment of Ph-like B-Cell Acute Lymphoblastic Leukemia with Overexpression of CRLF2
- Author
-
Stoian, Cornelia, Coats, Jacqueline S., Vidales, Veriah, Baez, Ineavely, Personius, Juliette, Choi, Hannah, Liu, Lawrence, Chirshev, Evgeny, Alkashgari, Hossam, Ng, Brandon, Esmeralda, Garcia, Becerra, Benjamin, Chavan, Rishikesh, Kamal, Muhammad Omair, Gohar, Shadi Farzin, Dovat, Sinisa, and Payne, Kimberly
- Abstract
Ph-like B-cell acute lymphoblastic leukemia (B-ALL) is associated with poor outcomes and high relapse rates. Approximately 50% of Ph-like B-ALL cases occur due to genetic alterations leading to overexpression of the cytokine receptor, CRLF2. B-ALL with overexpression of CRLF2 (CRLF2 B-ALL) occurs 5 times more often in Hispanic children than others, is prevalent in adolescents and young adults, and makes up ~1/3 of adult B-ALL. CRLF2, together with the IL-7Rα, forms a receptor complex that can be activated by circulating TSLP cytokine in patients. The human CRLF2 receptor is not activated by mouse TSLP so classic patient-derived xenografts (PDX) do not model TSLP-induced CRLF2 signaling that occurs in patients. CRLF2-mediated JAK/STAT and PI3/AKT/mTOR signals are believed to contribute to survival and proliferation of leukemia cells. We developed a novel PDX model of CRLF2 B-ALL that allows us to vary circulating levels of human TSLP (+T PDX). Primary CRLF2 B-ALL cells injected into +T PDX with circulating human TSLP (hTSLP) levels similar to pediatric leukemia patients (~4-10 pg/ml), engrafted well and showed a gene expression pattern that was more similar to the original patient sample than when injected into classic PDX. To our surprise, when +T PDX expressed physiological, but elevated levels of hTSLP (> 40 pg/ml, upper end of range reported in healthy children), CRLF2 B-ALL cells were essentially eliminated, but grew robustly in PDX without hTSLP (-T PDX). These results have been observed in 4 independent experiments for a total of 17 +T PDX and 12 -T PDX mice produced using CRLF2 B-ALL cells from two different Hispanic pediatric patients with CRLF2 B-ALL. We hypothesize that anti-leukemia effects observed at hTSLP concentrations above 40 pg/ml are mediated via TSLP-induced upregulation of the Suppressor of Cytokine Signaling (SOCS) genes. SOCS genes encode a family of proteins that regulate cytokine signaling via negative feedback through multiple mechanisms including ubiquitin-mediated degradation of JAKs and cytokine receptor components. Using the CRLF2 B-ALL cell lines, MUTZ5 and CALL-4, we found that SOCS family proteins encoded by the SOCS1 and SOCS3 genes were upregulated following culture with 15 ng/ml hTSLP, as compared to controls without hTSLP. Similarly, primary CRLF2 B-ALL cells from Hispanic pediatric patients cultured with TSLP showed upregulation of SOCS1 and SOCS3 mRNA and proteins. Next, we determined whether the upregulation of SOCS proteins was accompanied by a loss of CRLF2-mediated signals. We found that CRLF2 B-ALL cell lines and primary cells cultured with hTSLP lost the ability to upregulate STAT5 and S6 phosphorylation following hTSLP stimulation. Further, cells cultured with TSLP showed a loss of cytokine receptors as well as STAT5 phosphorylation levels that were below the baseline observed in leukemia cells never exposed to hTSLP. These data suggest that TSLP exerts anti-leukemia effects by shutting down CRLF2-mediated signals and that this shut down may occur through SOCS-mediated degradation of cytokine receptor components and/or degradation of the mutant JAK2 that provides constitutively low level STAT5 activation in these CRLF2 B-ALL cell lines and in a majority of patients with this disease. In summary, these results provide evidence that elevated hTSLP exerts a therapeutic effect on CRLF2 B-ALL and suggest that this occurs via SOCS-mediated suppression of the CRLF2 signaling pathway. These studies identify the human TSLP cytokine as a potential biologic therapy to treat CRLF2 B-ALL and reduce cancer health disparities for Hispanic children with CRLF2 B-ALL. Supported by 1R01CA209829.
- Published
- 2017
- Full Text
- View/download PDF
20. Significance of Stereochemistry in Short Antimicrobial Peptides
- Author
-
Smith, Virginia F., Bishop, Barney M., Papanastasiou, E. Andrew, Jehangir, Myra, Choi, Hannah, and van Hoek, Monique L.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.